Inclusion Criteria:  Cytological diagnosis of acute myeloid leukemia (AML) with indication for a first-line allo-HSCTs transplant Patient affiliated to the social security system For women of childbearing age, use of reliable contraception throughout the study in accordance with the CPR of the drugs used. The patient must be able to comply with study visits and per protocol procedures Patient who has been informed of the study and has signed his informed consent  Exclusion Criteria:  Person under guardianship or curatorship, or unable to understand the purpose of the study. Hematologic malignancies other than AML History of neoplasia with bone involvement (sarcoma, multiple myeloma, metastasis...) and/or any solid cancer less than 5 years old History of fracture of the femoral neck prior to the diagnosis of hematologic malignancies Known bone involvement related to AML at diagnosis Primary or secondary osteoporosis known to the diagnosis of hematologic malignancies Corticotherapy > 3 months at a dose > 7.5mg/day prior to the diagnosis of hematological disease Autograft or anterior allograft Pathologies influencing bone metabolism: known inflammatory rheumatism (rheumatoid arthritis, ...), primary hyperparathyroidism, chronic renal failure (GFR < or = at 30ml / min / 1.73m2) Pregnant or lactating woman